Načítá se...
Treatment of rheumatoid arthritis by molecular-targeted agents: efficacy and limitations
Rheumatoid arthritis (RA) is characterized by chronic synovial inflammation due to unknown causes. Conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), biological DMARDs (bDMARDs), and tofacitinib, a targeted sDMARD, can be used to treat RA. In clinical trials, molecular-targeted...
Uloženo v:
| Vydáno v: | J Orthop Sci |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer Japan
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4653232/ https://ncbi.nlm.nih.gov/pubmed/26404390 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00776-015-0766-9 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|